ArticleIn vitro models2026
Development of a functional sarcopenia model utilizing a microcantilever microphysiological system as a phenotypic disease model.
Article in In vitro models, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development of a Multi-Organ Microphysiological (MPS) Model to Study Age-Related Comorbidities.Advanced biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Sarcopenia is a skeletal muscle (SKM) condition marked by reduced muscle mass and function and is often observed as a comorbidity with inflammatory conditions. Methods: We have developed a defined in vitro functional model to study sarcopenia by incubating human-induced pluripotent stem cell-derived SKM cells with 3 nM TNF-alpha (TNFα) for 96 h. The long-term effects of this treatment were studied for up to 32 days in culture. Muscle function was evaluated by measuring myotube width as well as microcantilever contraction amplitude, force, and fatigue index. Results: This model revealed the maintenance of a significant reduction in myotube width for 32 days after TNF-α treatment; moreover, a decrease in myotube contraction amplitude and an increase in fatigue indices were recorded for 32 days. In addition, disease progression and tissue degradation of the sarcopenic conditions were monitored for higher reactive oxygen species production for both acute (day 4) and chronic (day 40) timelines. Conclusion: This is the first microphysiological system for sarcopenia evaluation that can be used to evaluate therapeutics. This device can now be combined in a multi-organ microphysiological system to study sarcopenia induced by an inflammatory response from other organs or as a comorbidity in the platform. Graphical Abstract: Development of the first defined in vitro functional model of sarcopenia on a microcantilever platform. This study recapitulates physiological signatures of disease progression characterized by loss of muscle mass and function and an increase in reactive oxygen species.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.